$591 | SAVE $104 | Single User
$1186 | SAVE $209 | Global License

Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Nov 2013 | 82 | In Stock

Introduction

Scope



Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, interferon-sparing hepatitis C therapies, with this success expected to be centred on its combination sofosbuvir plus ledipasvir franchise. Final Phase III data for this combination therapy are expected to emerge in early 2014, with potential approval secured towards the end of next year.


However, impressive Phase III data released earlier this week from the first of six late-stage studies for AbbVie’s ‘3D’ regimen - which puts the company on a similar regulatory timescale to Gilead – suggest that the US biotech will not be competing completely on its own terms. Similarly, analysts have recently pointed out that Merck & Co. could also emerge as a viable competitor in the genotype 1 space.


A number of analysts noted that data from the SAPPHIRE study confirm AbbVie’s competitive position among the first generation of interferon-free therapies for genotype 1 patients, given the efficacy and safety of its regimen.


A consensus appears to be emerging that AbbVie could secure a 10 percent to 15 percent share of the market, despite its regimen being more complex to dose – a multi-tablet (six) therapy dosed twice-daily (versus Gilead’s once-daily fixed-dose combination) – and including ritonavir – which can increase drug-drug interactions.


Analysts at Goldman Sachs argue that Merck’s Victrelis previously achieved a 20 percent to 30 percent share of the hepatitis C market, despite being a "worse regimen" relative to Vertex’s Incivek than AbbVie’s ‘3D’ regimen is to sofosbuvir + ledipasvir. Possibly reflecting a pharma to biotech disconnect, they also point to 2015 forecast hepatitis C sales for Gilead being 10 times those currently anticipated for AbbVie.


Puchase Reasons


To gain a better perspective on how physicians expect to use interferon-free regimens, FirstWord is polling gastroenterologists/hepatologists and infectious disease specialists based in the US and EU5. Specifically the poll will ask them:


  • What percentage of diagnosed but untreated genotype 1 hepatitis C patients they expect to warehouse until interferon-free therapies are made available – anticipated in late 2014/early 2015?

  • Assuming cure rates are comparable, to what percentage of genotype 1 patients they would prescribe an interferon-sparing, once-daily, single-tablet therapy rather than an interferon-sparing multi-tablet therapy dosed five-times daily?

  • What their level of concern is regarding ritonavir-boosting in future interferon-sparing regimens?

  • Whether prescribing Gilead’s sofosbuvir during 2014 will positively influence their subsequent prescribing habits for an interferon-free sofosbuvir-based regimen in genotype 1 patients?

  • To what percentage of genotype 1 patients they expect to prescribe Gilead’s sofosbuvir + ledipasvir fixed-dose combination?
  • Table of Contents
    for Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    82 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...